Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb

Executive Summary

Signs agreement with the Italian firm Indena to derive anti-cancer agent taxol from needles and twigs of yew tree species in Europe and Asia, the company announces on June 24. Taxol extracted from the bark of Pacific yew trees has shown activity against ovarian and breast cancer. Under the new agreement, Indena, based in Milan, will extract the natural chemical 10-deacetylbaccatin III, a precursor for taxol, from the renewable biomass of yew twigs and needles and export it to the U.S. BMS will then process the natural chemical into taxol through a semi-synthetic method licensed from Florida State University last year. BMS, which plans to file an NDA for natural taxol in the next few months, hopes to file an NDA for this new source in 1993.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel